by Jordana Choucair | Mar 8, 2022 | Life Sciences
Moderna Inc. suggested it is ready to enforce its COVID-19 vaccine patents in wealthier countries, but didn’t specify a timeline. According to CEO Stéphane Bancel, Moderna is open to licensing its patents in higher-income nations on “commercially...
by Jordana Choucair | Mar 8, 2022 | Life Sciences
Bancel also said that Moderna is preparing to launch human trials by 2025 for vaccines targeting 15 viruses and other pathogens that “threaten global health.” He said the $300 million effort seeks to complete early dose and safety testing in case any of...
by Jordana Choucair | Mar 4, 2022 | Life Sciences
Civica Rx, the nonprofit generic drug company created by a consortium of hospitals, announced that it plans to lower the cost of insulin by making it on its own. Civica plans to manufacture and distribute three different kinds of insulin at a cost of no more than $30...
by Jordana Choucair | Mar 3, 2022 | Life Sciences
A new study found that a booster shot of either the Pfizer Inc.-BioNTech SE or Moderna Inc. COVID-19 vaccines restored protection against symptomatic sickness caused by the omicron variant. However, just two doses of either vaccine brand were only minimally effective:...
by Jordana Choucair | Mar 2, 2022 | Life Sciences
A group of 13 lawmakers called on the Pharmaceutical Research and Manufacturers of America (PhRMA) to account for the “troubling price increases for brand name drugs” in January. The group, led by Senators Elizabeth Warren and Amy Klobuchar, accused...
by Jordana Choucair | Mar 2, 2022 | Life Sciences
The National Institutes of Health ordered a major review of federal biosecurity policies for experiments involving potentially dangerous pathogens. The agency hopes to gather recommendations by the end of 2022 on where to draw the line on potentially risky research....
Recent Comments